Welcome to our dedicated page for Relay Therapeutics SEC filings (Ticker: RLAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Relay Therapeutics, Inc. filings document the regulatory record of a clinical-stage precision-medicine company developing small molecule programs for cancer and genetic disease. Form 8-K reports include operating and financial results, Regulation FD clinical updates for zovegalisib, FDA Breakthrough Therapy designation disclosure, material agreements, capital-structure matters, and governance changes.
Proxy materials describe board composition, committee structure, executive compensation, equity awards, shareholder voting matters, and related governance policies. Other filings address amendments to bylaws, including exclusive-forum provisions, and securities disclosures tied to RLAY common stock and its development-stage pipeline.
Casdin Capital and related entities reported a significant passive stake in Relay Therapeutics, Inc. They disclosed beneficial ownership of 13,003,574 shares of common stock, representing 7.5% of the company. Casdin Partners Master Fund, L.P. directly holds 12,585,000 shares, or 7.3% of the class.
The reporting persons have no sole voting or dispositive power but share voting and dispositive power over these shares. All reported securities are directly owned by advisory clients of Casdin Capital, and the filers certify the holdings are not for the purpose of changing or influencing control of Relay Therapeutics.
Relay Therapeutics, Inc. (RLAY) received an updated Schedule 13G/A showing Casdin-affiliated investors as significant shareholders. Casdin Capital, LLC, Casdin Partners GP, LLC and Eli Casdin each report beneficial ownership of 13,003,574 shares of common stock, representing 7.5% of the class as of 12/31/2025. Casdin Partners Master Fund, L.P. reports 12,585,000 shares, or 7.3% of the class. All reported shares are held by advisory clients of Casdin Capital, and the filers certify the holdings are passive and not intended to change or influence control of Relay Therapeutics.
Relay Therapeutics, Inc. reported that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to its drug candidate zovegalisib (RLY-2608) in combination with fulvestrant. This designation covers adults with PIK3CA mutant HR+/HER2- locally advanced or metastatic breast cancer that has recurred or progressed after treatment with a CDK4/6 inhibitor.
Relay Therapeutics President of R&D Donald A. Bergstrom reported automatic sales of common stock to cover tax withholding on recently vested RSUs. On January 27, 2026, 18,895 shares were sold at $7.62 per share, and on January 28, 2026, 2,686 shares were sold at $8.45 per share.
The footnotes state these transactions were executed without his discretion under company policies when 59,550 and 9,072 RSUs vested. After these transactions, he beneficially owned 420,047 shares, including 20,049 shares underlying RSUs.
Relay Therapeutics officer reports ESPP purchase and tax sales. Chief Corporate Development Officer Peter Rahmer bought 994 shares of Relay Therapeutics common stock on December 31, 2025 under the 2020 Employee Stock Purchase Plan at $2.99 per share, a transaction the company notes is voluntarily reported.
On January 27, 2026 he sold 11,684 shares at $7.62 per share, and on January 28, 2026 he sold 1,354 shares at $8.45 per share. Footnotes state both sales were made only to cover income tax withholding on vesting RSUs, with no discretion over the sales. After these transactions, he beneficially owned 276,610 shares, including shares underlying RSUs.
Relay Therapeutics Chief Financial Officer Thomas Catinazzo reported automatic share sales tied to restricted stock unit (RSU) vesting. On January 27, 2026, he sold 13,820 shares of common stock at $7.62 per share, and on January 28, 2026, he sold 1,695 shares at $8.45 per share.
Footnotes state both transactions were sales of shares to cover income tax withholding obligations upon the vesting of 42,394 and 5,724 RSUs, and that he had no discretion over the sales under company policies. After these transactions, he beneficially owned 250,996 and then 249,301 shares, including shares underlying RSUs.
Relay Therapeutics, Inc. reported that Donald A. Bergstrom, its President of R&D, received a grant of stock options on January 13, 2026. The award covers 575,000 stock options, each representing the right to buy one share of common stock at an exercise price of $7.94 per share. Following this grant, Bergstrom beneficially owns 575,000 derivative securities directly.
The options are designed to vest over time. According to the disclosure, the shares underlying this option will vest in sixteen equal quarterly installments after January 13, 2026, and each vesting date requires Bergstrom to continue his service with the company. This structure aligns the award with ongoing tenure and performance in his executive role.
Relay Therapeutics, Inc. reported an insider equity award for Chief Corporate Development Officer Peter Rahmer. On January 13, 2026, he received a stock option covering 475,000 shares of common stock at an exercise price of $7.94 per share.
According to the filing, the shares underlying this option vest in sixteen equal quarterly installments after January 13, 2026, contingent on his continued service with the company through each vesting date. Following this grant, Rahmer beneficially owned 475,000 derivative securities directly in the form of this stock option.
Relay Therapeutics, Inc. reported that President and CEO Sanjiv Patel received a stock option grant. On January 13, 2026, he was awarded an option to buy 1,450,000 shares of Relay Therapeutics common stock at an exercise price of $7.94 per share. The filing states that the shares underlying this option will vest in sixteen equal quarterly installments after January 13, 2026, so long as he continues to serve with the company through each vesting date. Following this grant, he beneficially owned 1,450,000 derivative securities directly.
Relay Therapeutics reported that its Chief Financial Officer, Thomas Catinazzo, received a new stock option grant. On 01/13/2026, he was awarded a stock option to buy 400,000 shares of common stock at $7.94 per share. After this grant, he beneficially owns 400,000 derivative securities directly.
The option shares will vest in sixteen equal quarterly installments after January 13, 2026, and each installment requires his continued service with the company through the applicable vesting date. This filing records the award and resulting beneficial ownership rather than any share sale.